Sanofi and GlaxoSmithKline say their COVID-19 vaccine triggers a strong immune response, boosting the program’s potential for late arrivals as a booster dose

0
15
Sanofi and GlaxoSmithKline say their COVID-19 vaccine triggers a strong immune response, boosting the program’s potential for late arrivals as a booster dose


    Les deux géants de la fabrication de vaccins prévoient de lancer une étude sur 35 000 personnes dans les prochaines semaines, dans le but d'obtenir l'approbation avant la fin de l'année.
  </p><div>
    <ul class="summary-list"><li>Sanofi et GlaxoSmithKline ont déclaré que leur vaccin expérimental COVID-19 avait réussi un essai à mi-parcours. </li>
  • The pharmacy giants plan to launch a pivotal study with 35,000 volunteers in the coming weeks.
  • The shot suffered from disappointing data and delays in 2020. Companies are now hoping for approval by the end of the year.
  • See more stories on the Insider business page.
  • One of the world’s most closely watched coronavirus vaccination programs reported positive data from a mid-term clinical trial on Monday, paving the way for the start of a massive human trial that could clear the shot before the end of this year.

    Sanofi and GlaxoSmithKline, two of the world’s largest vaccine makers, said in a press release that their investigational coronavirus vaccine led to strong immune responses at all ages in a study that recruited 722 volunteers. This is much needed positive news for the two industry leaders, who saw their vaccination effort delayed by disappointing data announced in December, and are far behind rivals like Moderna, Pfizer-BioNTech and Johnson & Johnson.

    Read more: GlaxoSmithKline tripped with shots from COVID-19. He now faces an exodus of American talent and an uncertain future as a world leader in vaccines.

    The companies have not published specific data on the antibody response, published the results in a peer-reviewed medical journal, or published an article on a pre-print server.

    Emma Walmsley, PDG de GSK
    Microsoft

    Instead, the companies issued a press release describing the neutralizing antibody responses as “comparable to those generated by natural infection.”

    Neutralizing antibodies are the anti-virus proteins that play an essential role in our immune response. GSK and Sanofi added that young volunteers generally had stronger immune responses to the vaccine.

    The two pharmaceutical giants plan to launch in the coming weeks a final phase clinical study, called a phase 3 trial, which will recruit more than 35,000 people. They also plan to simultaneously conduct smaller studies that test their vaccine, including versions designed to neutralize specific variants of the coronavirus, as boosters in people who have previously been immunized.

    If all goes according to plan, Sanofi and GSK expect their vaccine to be approved in October, November or December 2021, the companies said.

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here